These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23373782)

  • 41. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
    Suppiah R; Srkalovic JG; Hussein MA
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):301-5. PubMed ID: 16507207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
    Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunomodulatory drugs in AL amyloidosis.
    Jelinek T; Kufova Z; Hajek R
    Crit Rev Oncol Hematol; 2016 Mar; 99():249-60. PubMed ID: 26806146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
    Zeidner JF; Foster MC
    Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
    Costa BA; Mouhieddine TH; Richter J
    Target Oncol; 2022 Jul; 17(4):383-405. PubMed ID: 35771402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
    Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
    Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Novel targeted therapy in multiple myeloma].
    Izumi T
    Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
    Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
    ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
    Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update on the use of lenalidomide for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2015; 16(12):1865-77. PubMed ID: 26165832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
    Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
    Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
    D'Souza C; Prince HM; Neeson PJ
    Front Immunol; 2021; 12():632399. PubMed ID: 33746969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.
    Mitsiades CS; Chen-Kiang S
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S5-13. PubMed ID: 23806982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.